Correlation  ||| S:0 E:12 ||| NN
between  ||| S:12 E:20 ||| IN
histopathological  ||| S:20 E:38 ||| JJ
aspects  ||| S:38 E:46 ||| NNS
of  ||| S:46 E:49 ||| IN
periodontitis  ||| S:49 E:63 ||| NN
and  ||| S:63 E:67 ||| CC
biochemical  ||| S:67 E:79 ||| JJ
changes  ||| S:79 E:87 ||| NNS
of  ||| S:87 E:90 ||| IN
oxidative  ||| S:90 E:100 ||| NNS
stress  ||| S:100 E:107 ||| VBP
The  ||| S:107 E:111 ||| DT
aim  ||| S:111 E:115 ||| NN
of  ||| S:115 E:118 ||| IN
this  ||| S:118 E:123 ||| DT
paper  ||| S:123 E:129 ||| NN
is  ||| S:129 E:132 ||| VBZ
to  ||| S:132 E:135 ||| TO
assess  ||| S:135 E:142 ||| VB
the  ||| S:142 E:146 ||| DT
histopathological  ||| S:146 E:164 ||| JJ
changes  ||| S:164 E:172 ||| NNS
and  ||| S:172 E:176 ||| CC
the  ||| S:176 E:180 ||| DT
condition  ||| S:180 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
oxidative  ||| S:193 E:203 ||| JJ
stress  ||| S:203 E:210 ||| NN
in  ||| S:210 E:213 ||| IN
the  ||| S:213 E:217 ||| DT
saliva  ||| S:217 E:224 ||| NN
of  ||| S:224 E:227 ||| IN
the  ||| S:227 E:231 ||| DT
patients  ||| S:231 E:240 ||| NNS
with  ||| S:240 E:245 ||| IN
periodontal  ||| S:245 E:257 ||| JJ
disease ||| S:257 E:264 ||| NN
.  ||| S:264 E:266 ||| .
We  ||| S:266 E:269 ||| PRP
have  ||| S:269 E:274 ||| VBP
carried  ||| S:274 E:282 ||| VBN
out  ||| S:282 E:286 ||| RP
our  ||| S:286 E:290 ||| PRP$
research  ||| S:290 E:299 ||| NN
on  ||| S:299 E:302 ||| IN
two  ||| S:302 E:306 ||| CD
groups  ||| S:306 E:313 ||| NNS
of  ||| S:313 E:316 ||| IN
patients  ||| S:316 E:325 ||| NNS
with  ||| S:325 E:330 ||| IN
periodontitis  ||| S:330 E:344 ||| NNS
( ||| S:344 E:345 ||| -LRB-
a  ||| S:345 E:347 ||| DT
group  ||| S:347 E:353 ||| NN
of  ||| S:353 E:356 ||| IN
16  ||| S:356 E:359 ||| CD
patients  ||| S:359 E:368 ||| NNS
with  ||| S:368 E:373 ||| IN
stage  ||| S:373 E:379 ||| NN
I  ||| S:379 E:381 ||| PRP
periodontitis  ||| S:381 E:395 ||| VBP
and  ||| S:395 E:399 ||| CC
a  ||| S:399 E:401 ||| DT
group  ||| S:401 E:407 ||| NN
of  ||| S:407 E:410 ||| IN
16  ||| S:410 E:413 ||| CD
patients  ||| S:413 E:422 ||| NNS
with  ||| S:422 E:427 ||| IN
stage  ||| S:427 E:433 ||| NN
II  ||| S:433 E:436 ||| NNP
periodontitis ||| S:436 E:449 ||| CD
) ||| S:449 E:450 ||| -RRB-
,  ||| S:450 E:452 ||| ,
who  ||| S:452 E:456 ||| WP
we  ||| S:456 E:459 ||| PRP
have  ||| S:459 E:464 ||| VBP
compared ||| S:464 E:472 ||| VBN
,  ||| S:472 E:474 ||| ,
using  ||| S:474 E:480 ||| VBG
samples  ||| S:480 E:488 ||| NNS
of  ||| S:488 E:491 ||| IN
saliva  ||| S:491 E:498 ||| NN
and  ||| S:498 E:502 ||| CC
serum ||| S:502 E:507 ||| NN
,  ||| S:507 E:509 ||| ,
to  ||| S:509 E:512 ||| TO
a  ||| S:512 E:514 ||| DT
group  ||| S:514 E:520 ||| NN
of  ||| S:520 E:523 ||| IN
15  ||| S:523 E:526 ||| CD
volunteers  ||| S:526 E:537 ||| NNS
without  ||| S:537 E:545 ||| IN
any  ||| S:545 E:549 ||| DT
dental  ||| S:549 E:556 ||| JJ
restorations ||| S:556 E:568 ||| NN
.  ||| S:568 E:570 ||| .
To  ||| S:570 E:573 ||| TO
dose  ||| S:573 E:578 ||| VB
MDA ||| S:578 E:581 ||| NNP
,  ||| S:581 E:583 ||| ,
we  ||| S:583 E:586 ||| PRP
used  ||| S:586 E:591 ||| VBD
thiobarbituric  ||| S:591 E:606 ||| JJ
acid  ||| S:606 E:611 ||| NN
method  ||| S:611 E:618 ||| NN
and  ||| S:618 E:622 ||| CC
for  ||| S:622 E:626 ||| IN
determination  ||| S:626 E:640 ||| NN
of  ||| S:640 E:643 ||| IN
ceruloplasmin  ||| S:643 E:657 ||| VBG
the  ||| S:657 E:661 ||| DT
Ravin ||| S:661 E:666 ||| NNP
's  ||| S:666 E:669 ||| POS
method ||| S:669 E:675 ||| NN
.  ||| S:675 E:677 ||| .
For  ||| S:677 E:681 ||| IN
histopathological  ||| S:681 E:699 ||| JJ
examination ||| S:699 E:710 ||| NN
,  ||| S:710 E:712 ||| ,
the  ||| S:712 E:716 ||| DT
periodontal  ||| S:716 E:728 ||| JJ
fragments  ||| S:728 E:738 ||| NNS
were  ||| S:738 E:743 ||| VBD
immediately  ||| S:743 E:755 ||| RB
underwent  ||| S:755 E:765 ||| VBD
for  ||| S:765 E:769 ||| IN
fixation  ||| S:769 E:778 ||| NN
in  ||| S:778 E:781 ||| IN
10 ||| S:781 E:783 ||| CD
%  ||| S:783 E:785 ||| NN
neutral  ||| S:785 E:793 ||| JJ
formalin  ||| S:793 E:802 ||| JJ
solution  ||| S:802 E:811 ||| NN
and  ||| S:811 E:815 ||| CC
then ||| S:815 E:819 ||| RB
,  ||| S:819 E:821 ||| ,
they  ||| S:821 E:826 ||| PRP
were  ||| S:826 E:831 ||| VBD
included  ||| S:831 E:840 ||| VBN
in  ||| S:840 E:843 ||| IN
paraffin  ||| S:843 E:852 ||| NNS
using  ||| S:852 E:858 ||| VBG
the  ||| S:858 E:862 ||| DT
conventional  ||| S:862 E:875 ||| JJ
histological  ||| S:875 E:888 ||| JJ
technique ||| S:888 E:897 ||| NN
.  ||| S:897 E:899 ||| .
The  ||| S:899 E:903 ||| DT
group  ||| S:903 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
patients  ||| S:912 E:921 ||| NNS
with  ||| S:921 E:926 ||| IN
stage  ||| S:926 E:932 ||| NN
II  ||| S:932 E:935 ||| NNP
periodontitis  ||| S:935 E:949 ||| VBD
presented  ||| S:949 E:959 ||| VBN
lower  ||| S:959 E:965 ||| JJR
values  ||| S:965 E:972 ||| NNS
of  ||| S:972 E:975 ||| IN
salivary  ||| S:975 E:984 ||| JJ
MDA  ||| S:984 E:988 ||| NNS
compared  ||| S:988 E:997 ||| VBN
to  ||| S:997 E:1000 ||| TO
the  ||| S:1000 E:1004 ||| DT
group  ||| S:1004 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
patients  ||| S:1013 E:1022 ||| NNS
with  ||| S:1022 E:1027 ||| IN
stage  ||| S:1027 E:1033 ||| NN
I  ||| S:1033 E:1035 ||| PRP
periodontitis ||| S:1035 E:1048 ||| VBD
.  ||| S:1048 E:1050 ||| .
Patients  ||| S:1050 E:1059 ||| NNS
with  ||| S:1059 E:1064 ||| IN
stage  ||| S:1064 E:1070 ||| NN
I  ||| S:1070 E:1072 ||| PRP
periodontitis  ||| S:1072 E:1086 ||| VBP
presented  ||| S:1086 E:1096 ||| VBN
a  ||| S:1096 E:1098 ||| DT
significantly  ||| S:1098 E:1112 ||| RB
increased  ||| S:1112 E:1122 ||| VBN
concentration  ||| S:1122 E:1136 ||| NN
of  ||| S:1136 E:1139 ||| IN
MDA  ||| S:1139 E:1143 ||| NNP
in  ||| S:1143 E:1146 ||| IN
the  ||| S:1146 E:1150 ||| DT
serum  ||| S:1150 E:1156 ||| NN
compared  ||| S:1156 E:1165 ||| VBN
to  ||| S:1165 E:1168 ||| TO
the  ||| S:1168 E:1172 ||| DT
control  ||| S:1172 E:1180 ||| NN
group ||| S:1180 E:1185 ||| NN
,  ||| S:1185 E:1187 ||| ,
but  ||| S:1187 E:1191 ||| CC
considerably  ||| S:1191 E:1204 ||| RB
lower  ||| S:1204 E:1210 ||| JJR
concentrations  ||| S:1210 E:1225 ||| NNS
compared  ||| S:1225 E:1234 ||| VBN
to  ||| S:1234 E:1237 ||| TO
patients  ||| S:1237 E:1246 ||| NNS
with  ||| S:1246 E:1251 ||| IN
stage  ||| S:1251 E:1257 ||| NN
II  ||| S:1257 E:1260 ||| NNP
periodontitis ||| S:1260 E:1273 ||| NN
.  ||| S:1273 E:1275 ||| .
The  ||| S:1275 E:1279 ||| DT
values  ||| S:1279 E:1286 ||| NNS
of  ||| S:1286 E:1289 ||| IN
serum  ||| S:1289 E:1295 ||| JJ
ceruloplasmin  ||| S:1295 E:1309 ||| NNS
do  ||| S:1309 E:1312 ||| VBP
not  ||| S:1312 E:1316 ||| RB
present  ||| S:1316 E:1324 ||| VB
statistically  ||| S:1324 E:1338 ||| RB
important  ||| S:1338 E:1348 ||| JJ
changes  ||| S:1348 E:1356 ||| NNS
in  ||| S:1356 E:1359 ||| IN
patients  ||| S:1359 E:1368 ||| NNS
with  ||| S:1368 E:1373 ||| IN
stage  ||| S:1373 E:1379 ||| NN
I  ||| S:1379 E:1381 ||| PRP
periodontitis  ||| S:1381 E:1395 ||| VBP
compared  ||| S:1395 E:1404 ||| VBN
to  ||| S:1404 E:1407 ||| TO
those  ||| S:1407 E:1413 ||| DT
suffering  ||| S:1413 E:1423 ||| NN
from  ||| S:1423 E:1428 ||| IN
stage  ||| S:1428 E:1434 ||| NN
II  ||| S:1434 E:1437 ||| NNP
periodontitis  ||| S:1437 E:1451 ||| NN
and  ||| S:1451 E:1455 ||| CC
to  ||| S:1455 E:1458 ||| TO
those  ||| S:1458 E:1464 ||| DT
from  ||| S:1464 E:1469 ||| IN
the  ||| S:1469 E:1473 ||| DT
group  ||| S:1473 E:1479 ||| NN
control ||| S:1479 E:1486 ||| NN
.  ||| S:1486 E:1488 ||| .
MDA  ||| S:1488 E:1492 ||| NNP
is  ||| S:1492 E:1495 ||| VBZ
not  ||| S:1495 E:1499 ||| RB
a  ||| S:1499 E:1501 ||| DT
product  ||| S:1501 E:1509 ||| NN
of  ||| S:1509 E:1512 ||| IN
blood  ||| S:1512 E:1518 ||| NN
filtration  ||| S:1518 E:1529 ||| NN
as  ||| S:1529 E:1532 ||| IN
the  ||| S:1532 E:1536 ||| DT
concentration  ||| S:1536 E:1550 ||| NN
of  ||| S:1550 E:1553 ||| IN
MDA  ||| S:1553 E:1557 ||| NNP
in  ||| S:1557 E:1560 ||| IN
the  ||| S:1560 E:1564 ||| DT
bloodstream  ||| S:1564 E:1576 ||| NN
is  ||| S:1576 E:1579 ||| VBZ
bigger  ||| S:1579 E:1586 ||| JJR
than  ||| S:1586 E:1591 ||| IN
in  ||| S:1591 E:1594 ||| IN
the  ||| S:1594 E:1598 ||| DT
saliva ||| S:1598 E:1604 ||| NN
.  ||| S:1604 E:1606 ||| .
Tissue  ||| S:1606 E:1613 ||| NN
changes  ||| S:1613 E:1621 ||| NNS
and  ||| S:1621 E:1625 ||| CC
biochemical  ||| S:1625 E:1637 ||| JJ
aspects  ||| S:1637 E:1645 ||| NNS
are  ||| S:1645 E:1649 ||| VBP
strongly  ||| S:1649 E:1658 ||| RB
connected ||| S:1658 E:1667 ||| VBN
.  ||| S:1667 E:1669 ||| .
Removing  ||| S:1669 E:1678 ||| VBG
dental  ||| S:1678 E:1685 ||| JJ
plaque  ||| S:1685 E:1692 ||| NN
can  ||| S:1692 E:1696 ||| MD
prevent  ||| S:1696 E:1704 ||| VB
oral  ||| S:1704 E:1709 ||| JJ
infections ||| S:1709 E:1719 ||| NNS
.  ||| S:1719 E:1721 ||| .
